Tags

Type your tag names separated by a space and hit enter

Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis.
Mult Scler. 2012 Jun; 18(6):799-806.MS

Abstract

BACKGROUND

Some of the strongest associations with MS onset are for human herpesviruses, particularly Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6). Their role in MS clinical course is less clear, however.

METHODS

Prospective cohort of 198 persons with clinically definite MS, followed 2002-5, and serum samples obtained from all subjects at study entry to measure anti-HHV-6 and anti-EBV (Epstein-Barr nuclear antigen [EBNA] and viral capsid antigen [VCA]) IgG titers. Association with relapse evaluated using survival analysis; association with disability/progression evaluated using linear regression or multilevel mixed-effects linear regression.

RESULTS

For the 145 persons with relapsing-remitting MS followed beyond one review, anti-HHV-6 IgG titer was positively associated with the hazard of relapse with a dose-dependent trend (p = 0.003), not affected by adjustment for anti-EBV IgG titers, neither of which were independently associated with relapse. There was no significant association between anti-human herpesvirus IgG titers and baseline-measured disability scores, or change in disability scores; however, anti-HHV-6 IgG titers were 2.8 times higher among progressive-course females than progressive-course males.

DISCUSSION

These findings suggest that, in addition to a potential etiological role in MS, HHV-6 infection or the immune response to HHV-6 antigens may have an effect on the risk of MS relapses and possibly on progressive courses of MS. The observed effect was directly related to anti-HHV-6 IgG titers and may indicate that either HHV-6 infection or factors associated with an altered humoral immune response to HHV-6 may have an effect on MS clinical course. Anti-HHV-6 IgG titer may be a useful prognostic factor in relapsing-remitting MS clinical course.

Authors+Show Affiliations

1Menzies Research Institute Tasmania, University of Tasmania, Australia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22084489

Citation

Simpson, Steve, et al. "Anti-HHV-6 IgG Titer Significantly Predicts Subsequent Relapse Risk in Multiple Sclerosis." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 18, no. 6, 2012, pp. 799-806.
Simpson S, Taylor B, Dwyer DE, et al. Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis. Mult Scler. 2012;18(6):799-806.
Simpson, S., Taylor, B., Dwyer, D. E., Taylor, J., Blizzard, L., Ponsonby, A. L., Pittas, F., Dwyer, T., & van der Mei, I. (2012). Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 18(6), 799-806. https://doi.org/10.1177/1352458511428081
Simpson S, et al. Anti-HHV-6 IgG Titer Significantly Predicts Subsequent Relapse Risk in Multiple Sclerosis. Mult Scler. 2012;18(6):799-806. PubMed PMID: 22084489.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis. AU - Simpson,Steve,Jr AU - Taylor,Bruce, AU - Dwyer,Dominic E, AU - Taylor,Janette, AU - Blizzard,Leigh, AU - Ponsonby,Anne-Louise, AU - Pittas,Fotini, AU - Dwyer,Terence, AU - van der Mei,Ingrid, Y1 - 2011/11/14/ PY - 2011/11/16/entrez PY - 2011/11/16/pubmed PY - 2012/9/26/medline SP - 799 EP - 806 JF - Multiple sclerosis (Houndmills, Basingstoke, England) JO - Mult Scler VL - 18 IS - 6 N2 - BACKGROUND: Some of the strongest associations with MS onset are for human herpesviruses, particularly Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6). Their role in MS clinical course is less clear, however. METHODS: Prospective cohort of 198 persons with clinically definite MS, followed 2002-5, and serum samples obtained from all subjects at study entry to measure anti-HHV-6 and anti-EBV (Epstein-Barr nuclear antigen [EBNA] and viral capsid antigen [VCA]) IgG titers. Association with relapse evaluated using survival analysis; association with disability/progression evaluated using linear regression or multilevel mixed-effects linear regression. RESULTS: For the 145 persons with relapsing-remitting MS followed beyond one review, anti-HHV-6 IgG titer was positively associated with the hazard of relapse with a dose-dependent trend (p = 0.003), not affected by adjustment for anti-EBV IgG titers, neither of which were independently associated with relapse. There was no significant association between anti-human herpesvirus IgG titers and baseline-measured disability scores, or change in disability scores; however, anti-HHV-6 IgG titers were 2.8 times higher among progressive-course females than progressive-course males. DISCUSSION: These findings suggest that, in addition to a potential etiological role in MS, HHV-6 infection or the immune response to HHV-6 antigens may have an effect on the risk of MS relapses and possibly on progressive courses of MS. The observed effect was directly related to anti-HHV-6 IgG titers and may indicate that either HHV-6 infection or factors associated with an altered humoral immune response to HHV-6 may have an effect on MS clinical course. Anti-HHV-6 IgG titer may be a useful prognostic factor in relapsing-remitting MS clinical course. SN - 1477-0970 UR - https://www.unboundmedicine.com/medline/citation/22084489/Anti_HHV_6_IgG_titer_significantly_predicts_subsequent_relapse_risk_in_multiple_sclerosis_ L2 - https://journals.sagepub.com/doi/10.1177/1352458511428081?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -